Literature DB >> 8127120

Antibiotic prophylaxis in pulmonary surgery. A prospective randomized double-blind trial of flash cefuroxime versus forty-eight-hour cefuroxime.

A Bernard1, M Pillet, P Goudet, H Viard.   

Abstract

The aim of this study was to determine whether a 48-hour antibiotic prophylaxis regimen with a second-generation cephalosporin was more efficient than a flash antibiotic prophylaxis regimen in pulmonary operations. All the included patients underwent lung resection. Patients with preoperative infection were excluded. All the patients were given cefuroxime (1.5 gm intravenously) at the time of the anesthetic induction and again 2 hours later. The randomization was done postoperatively: group 1 was given placebo intravenously (n = 102) and group 2 was given cefuroxime intravenously (n = 101), each every 6 hours for 48 hours. The overall rate of infections was 46% in the 48-hour cefuroxime group versus 65% in the flash group (p = 0.005). The difference remained significant even after an adjustment with prognosis variables (p = 0.01). Six empyemas (6%) in the flash group were noted versus one (1%) in the 48-hour group (p = 0.03). From day 3 to day 8 after the operation, chest x-rays films were more often assessed as being normal in the flash group than in the 48-hour group (p = 0.005). On day 3 after operation, white blood cell counts were 13,020 +/- 1,220 elements/mm3 in the flash group versus 11,620 +/- 1,220 elements/mm3 in the 48-hour group (p = 0.03). A 48-hour antibiotic prophylaxis regimen decreases the rate of deep infections and particularly the rate of empyemas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8127120

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

Review 1.  Cost-effective prophylaxis of surgical infections.

Authors:  S R Norrby
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

2.  Bronchial colonization and complications after lung cancer surgery.

Authors:  Jelmer E Oor; Johannes M A Daniels; Yvette J Debets-Ossenkopp; Elly S M de Lange-de Klerk; Jan W A Oosterhuis; Chris Dickhoff; Koen J Hartemink
Journal:  Langenbecks Arch Surg       Date:  2016-08-02       Impact factor: 3.445

Review 3.  Perioperative antibiotics in thoracic surgery.

Authors:  Stephanie H Chang; Alexander S Krupnick
Journal:  Thorac Surg Clin       Date:  2011-10-20       Impact factor: 1.750

4.  Influence of prophylactic antibiotic duration on postoperative pneumonia following pulmonary lobectomy for non-small cell lung cancer.

Authors:  Hiroyuki Deguchi; Makoto Tomoyasu; Wataru Shigeeda; Yuka Kaneko; Hironaga Kanno; Hajime Saito
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

5.  Peri-Operative Prophylaxis in Patients of Neonatal and Pediatric Age Subjected to Cardiac and Thoracic Surgery: A RAND/UCLA Appropriateness Method Consensus Study.

Authors:  Sonia Bianchini; Laura Nicoletti; Sara Monaco; Erika Rigotti; Agnese Corbelli; Annamaria Colombari; Cinzia Auriti; Caterina Caminiti; Giorgio Conti; Maia De Luca; Daniele Donà; Luisa Galli; Silvia Garazzino; Alessandro Inserra; Stefania La Grutta; Laura Lancella; Mario Lima; Andrea Lo Vecchio; Gloria Pelizzo; Nicola Petrosillo; Giorgio Piacentini; Carlo Pietrasanta; Nicola Principi; Matteo Puntoni; Alessandro Simonini; Simonetta Tesoro; Elisabetta Venturini; Annamaria Staiano; Fabio Caramelli; Gaetano Domenico Gargiulo; Susanna Esposito
Journal:  Antibiotics (Basel)       Date:  2022-04-21

6.  Surgical site infections after lung resection: a prospective study of risk factors in 1,091 consecutive patients.

Authors:  Andrea Imperatori; Elisa Nardecchia; Lorenzo Dominioni; Daniele Sambucci; Sebastiano Spampatti; Giancarlo Feliciotti; Nicola Rotolo
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 7.  Video-assisted thoracic surgery complications.

Authors:  Mariusz P Łochowski; Józef Kozak
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-07-23       Impact factor: 1.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.